CompletedNCT02614547
A Study to Evaluate SAGE-547 in Participants With Severe Postpartum Depression
This study evaluated the safety and effectiveness of SAGE-547 for people with depression.
Medication studyAges 18–45United States
Understand this study
What did researchers investigate?
This study evaluated the safety and effectiveness of SAGE-547 for people with depression.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 45 years. Other eligibility criteria applied.
- Listed locations
- Atlanta and 3 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: December 15, 2015
- Recruitment status
- Completed
- Enrollment listed in the registry
- 21
- Sponsor
- Supernus Pharmaceuticals, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 45 Years
- Official registry ID
- NCT02614547
- Official title
Show the full official title
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating The Efficacy, Safety, And Pharmacokinetics Of SAGE-547 Injection In The Treatment Of Adult Female Subjects With Severe Postpartum Depression
Get this study by email
Recruitment & locations
CompletedAtlanta · Worcester · Chapel Hill
1 more locations
- Philadelphia
Questions about this study
What did researchers investigate?
This study evaluated the safety and effectiveness of SAGE-547 for people with depression.
Who is behind this study?
The study sponsor is Supernus Pharmaceuticals, Inc., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including SAGE-547 and Placebo.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 45 years. Other eligibility criteria applied.
